Affiliation:
1. College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
Abstract
Background:Due to its prevalence and negative impacts on both the economy and society, the diabetes mellitus (DM) has emerged as a worldwide concern. In light of this, the label-free quantification (LFQ) proteomics and diabetic marker selection methods have been applied to elucidate the underlying mechanisms associated with insulin resistance, explore novel protein biomarkers, and discover innovative therapeutic protein targets.Objective:The purpose of this manuscript is to review and analyze the recent computational advances and development of label-free quantification and diabetic marker selection in diabetes proteomics.Methods:Web of Science database, PubMed database and Google Scholar were utilized for searching label-free quantification, computational advances, feature selection and diabetes proteomics.Results:In this study, we systematically review the computational advances of label-free quantification and diabetic marker selection methods which were applied to get the understanding of DM pathological mechanisms. Firstly, different popular quantification measurements and proteomic quantification software tools which have been applied to the diabetes studies are comprehensively discussed. Secondly, a number of popular manipulation methods including transformation, pretreatment (centering, scaling, and normalization), missing value imputation methods and a variety of popular feature selection techniques applied to diabetes proteomic data are overviewed with objective evaluation on their advantages and disadvantages. Finally, the guidelines for the efficient use of the computationbased LFQ technology and feature selection methods in diabetes proteomics are proposed.Conclusion:In summary, this review provides guidelines for researchers who will engage in proteomics biomarker discovery and by properly applying these proteomic computational advances, more reliable therapeutic targets will be found in the field of diabetes mellitus.
Funder
Fundamental Research Funds for Central Universities
National Natural Science Foundation of China
National Key Research and Development Program of China
Publisher
Bentham Science Publishers Ltd.
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Medicine
Reference281 articles.
1. Miller B.R.; Nguyen H.; Hu C.J.; Lin C.; Nguyen Q.T.; New and emerging drugs and targets for type 2 diabetes: reviewing the evidence. Am Health Drug Benefits 2014,7(8),452-463
2. Pearson-Stuttard J.; Zhou B.; Kontis V.; Bentham J.; Gunter M.J.; Ezzati M.; Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol 2018,6(2),95-104
3. Kaur P.; Mittal A.; Nayak S.K.; Vyas M.; Mishra V.; Khatik G.L.; Current strategies and drug targets in the management of type 2 diabetes mellitus. Curr Drug Targets 2018,19(15),1738-1766
4. Gurudeeban S.; Satyavani K.; Ramanathan T.; Balasubramanian T.; Antidiabetic effect of a black mangrove species Aegiceras corniculatum in alloxan-induced diabetic rats. J Adv Pharm Technol Res 2012,3(1),52-56
5. Selvaraj G.; Kaliamurthi S.; Thirugnasambandan R.; Effect of Glycosin alkaloid from Rhizophora apiculata in non-insulin dependent diabetic rats and its mechanism of action: In vivo and in silico studies. Phytomedicine 2016,23(6),632-640
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献